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Autologous stem cell transplantation (ASCT) following high-dose chemotherapy (HDCT) is a 
cornerstone of first-line treatment in myeloma patients.1 Freezing of the hematopoietic stem 
cells (HSC) to bypass the time between stem cell collection and completion of HDCT is crucial. 
Due to the vulnerability of HSC to the freezing process, anti-freezing agents are mandatory, 
and between 5 and 10 vol% dimethyl-sulfoxide (DMSO) is commonly added.2-4 However, 
DMSO exerts toxic effects including nausea, vomiting, sedation and headaches,4–5 and 
triggers histamine release resulting in hypo-/hypertension, cardiac arrhythmia, rashes, renal 
failure, pulmonary edema, and bronchospasms. As toxicity of DMSO is dose-related, the 
recommended dose is 1 g/kg body weight (b.w.).4  
To provide reliable engraftment, a minimum of 2.0106 CD34+ HSC/kg b.w. is required. 
Usually, this number is collected during a single apheresis procedure, whereas some patients 
fail to reach this goal with a single-day apheresis procedure. Advanced age, high bone marrow 
infiltration, and a history of multiple induction lines including stem cell damaging compounds 
are associated with poor HSC mobilization.6 In patients with poor CD34+ mobilization at the 
first apheresis day, additional apheresis procedures are needed. This implies additional 
DMSO doses eventually exceeding the recommended maximum daily dose at retransfusion. 
In such patients, washing the autograft before transplantation or a reduced infusion rate can 
reduce side effects caused by increased DMSO administration.7-9  
At our center, the maximum transplantation volume is 300 mL per day with a DMSO 
concentration of 5% while avoiding washing and concentration steps. For patients with 
transfusion volumes exceeding these limits, ASCT is split over several days. At present, it 
remains unclear whether splitting the transplantation procedure is similarly beneficial as 
compared to a single day procedure, and the possible impact on outcome and engraftment is 
hardly studied. We retrospectively evaluated the effect of ASCT split over multiple days on 
survival outcomes and hematological recovery compared to a single day procedure in a large 
cohort of myeloma patients.  
Our study analyzed all consecutive myeloma patients undergoing first ASCT at the University 
Hospital Bern between 01/2006-12/2014 (Table S1). Patients received non-myelosuppressive 
mobilization chemotherapy at day +1 with vinorelbine or, alternatively, gemcitabine in patients 
with concurrent peripheral neuropathy (Table S2). Starting on day +4, patients received G-
CSF s.c. In patients with peripheral CD34+ counts <10/μL at day +8, the CXCR4 antagonist 
 
 
This article is protected by copyright. All rights reserved. 
plerixafor was added at day +9. HDCT was standard 200 mg/m2 melphalan followed by ASCT. 
Patients were offered maintenance therapy with 10 mg lenalidomide continuously for two 
years post-transplant. All patients gave written informed consent, and the ethics committee of 
Bern, Switzerland approved the study (KEK BE # 374/15).  
Between 2006 and 2014, 271 patients with multiple myeloma (265 patients), plasma cell 
leukemia (4 patients), or POEMS syndrome (2 patients) underwent a first ASCT. The majority 
(244 patients; 90%) received ASCT within a single day, and this group was termed Tx1. The 
Tx2-3 group comprised 23 patients receiving HSC on two days and four patients on three days. 
Both groups (Tx1 and Tx2-3) did not differ in clinical characteristics at diagnosis.  
Characteristics regarding HSC mobilization and CD34+ collection are summarized in Table 
S2. Plerixafor tended to be administered more frequently in Tx2-3 than Tx1 (p=0.0715). At the 
day of HSC collection, peripheral CD34+ counts were lower in Tx2-3. As expected, the final 
transplanted autograft volume was higher in Tx2-3 patients. The total amount of transplanted 
CD34+ cells/kg b.w. was lower in the Tx2-3 group, suggesting higher dilution of CD34+ cells 
(p<0.0001). The median recovery (Table S3) for neutrophils was 18 days for Tx2-3 and 12 days 
for Tx1 (p=0.0048), and for platelets 18 versus 14 days (p=0.0004). Tx2-3 patients had longer 
median hospitalization duration (23 versus 19 days; p=0.0006), and fever was more frequent 
in Tx2-3 (96% versus 76%; p=0.0131).  
The median follow-up for all patients was 56 months. Relapse-free survival (RFS) was 39 
months, and 169 relapses (62%) occurred so far. Median overall survival (OS) was 91 months, 
and 82 patients (30%) have died during follow-up. Tx2-3 patients had shorter median RFS (21 
versus 40 months for Tx1; p=0.0245), and shorter median OS with (55 versus 93 months; 
p=0.0134) (Table S3, Figure 1). The impact of the ISS staging system on survival outcomes 
is given in Figure S1.  
Maintenance with thalidomide or lenalidomide was administered at similar frequencies in Tx2-
3 and Tx1 (56% and 44%; p=0.3106), and a second ASCT was similarly performed (26% and 
35%; p=0.3795). Survival outcomes were not affected whether patients had a subsequent 
second ASCT or not (Figure S2). 
Obviously, there are alternatives to a multiple day transplantation procedure in patients with 
poor CD34+ mobilization. Among them, the autograft can be washed and concentrated to 
reduce the volume. Inevitably, this is associated with loss of CD34+ cells. Also, many centers 
perform single day procedures independently of the volume of the autograft. As demonstrated 
in a recent EBMT survey, the majority of transplant centers continue to use 10% DSMO for 
ASCT in myeloma and lymphoma patients, but a proportion of centers either use lower 
concentrations, 5% or 7.5%, or they wash and concentrate the cells before infusion.4 
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Furthermore, this survey indicated that patients in the highest quartile receiving DSMO had 
significantly more side effects. Better standardization of the preservation strategy with reduced 
DSMO concentration and increased awareness of DSMO dose-dependent toxicity was 
suggested to reduce toxicity and morbidity of the transplant procedure.  
In conclusion, multiple day transplantation was observed in roughly 10% of myeloma patients 
undergoing HSCT. Myeloma patients with multiple day transplantation procedures had later 
neutrophil and platelet engraftment, longer hospitalization duration, more frequently febrile 
episodes, and inferior OS and RFS.10 Therefore, multiple day transplantation procedures 
assign myeloma patients to a high-risk group, deserving careful follow-up. Whereas one is 
tempted to recommend such patients prolonged maintenance treatment,15 one might 
anticipate poor tolerance due to the reduced HSC pool in these patients. However, such 
conclusions should be tested in a prospective manner. Alternatives to multiple day 
transplantation procedures, e.g. reduction of the DSMO dose in the autografts in patients with 
high transplant volume, merit to be evaluated.  
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Figure 1: Relapse-free (PFS) and overall survival (OS). (A) RFS and (B) OS of myeloma 
patients is compared between patients receiving the ASCT as a single-day procedure (Tx1) as 
compared to patients receiving the autograft split over two or three days (Tx2-3).  
 
 
